ClinicalTrials.Veeva
Menu

Find clinical trials for Melanoma in Kansas City, KS

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Non-Small-Cell Lung Carcinoma
Renal Cell Carcinoma
Lung Cancer
Squamous Cell Carcinoma

Melanoma trials near Kansas City, KS, USA:

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

alone in participants with untreated, unresectable or metastatic melanoma. Participants randomized to the pembrolizumab monotherapy arm who ...

Enrolling
Melanoma
Unresectable Melanoma
Biological: Pembrolizumab with Optional Crossover Period
Biological: Lifileucel plus Pembrolizumab

Phase 3

Iovance Biotherapeutics

Kansas City, Kansas, United States and 32 other locations

binimetinib, and pembrolizumab) given together for the treatment of melanoma that:* is advanced or metastatic (spread to other parts of the ...

Active, not recruiting
Melanoma
Drug: Binimetinib
Drug: Encorafenib

Phase 3

Pfizer
Pfizer

Westwood, Kansas, United States and 227 other locations

lymphodepletion and interleukin-2, work for treating patients with melanoma that cannot be removed by surgery (unresectable) or that has spr...

Enrolling
Clinical Stage IV Cutaneous Melanoma AJCC v8
Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
Drug: Cyclophosphamide
Biological: Interleukin-2

Phase 2

University of Kansas
University of Kansas

Kansas City, Kansas, United States

(Spartalizumab (PDR001)), a BRAF inhibitor (dabrafenib) and a MEK inhibitor (trametinib) in unresectable or metastatic BRAF V600 mutant melanoma...

Active, not recruiting
Melanoma
Drug: Dabrafenib
Drug: Trametinib

Phase 3

Novartis
Novartis

Westwood, Kansas, United States and 178 other locations

to assess nivolumab plus relatlimab fixed-dose combination (FDC) versus nivolumab alone in participants with completely resected stage III-IV melanoma...

Active, not recruiting
Melanoma
Biological: Nivolumab
Biological: Nivolumab + Relatlimab Fixed Dose Combination

Phase 3

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Westwood, Kansas, United States and 171 other locations

This is a study to investigate the efficacy and safety of an infusion of IOV-4001 in adult participants with unresectable or metastatic melanoma...

Enrolling
Metastatic Melanoma
Unresectable Melanoma
Biological: IOV-4001

Phase 1, Phase 2

Iovance Biotherapeutics

Westwood, Kansas, United States and 7 other locations

combined with nivolumab on patients with unresectable or metastatic melanoma and eligible patients who are not adolescents or patients with ...

Enrolling
Unresectable or Metastatic Melanoma
Progressive Brain Metastasis
Drug: Placebo in combination with nivolumab
Drug: HBI-8000 in combination with nivolumab

Phase 3

HUYABIO

Kansas City, Missouri, United States and 141 other locations

(GNAQ/11) mutations or PRKC fusions, including metastatic uveal melanoma (MUM), cutaneous melanoma, colorectal cancer, and other so...

Enrolling
Metastatic Uveal Melanoma
Cutaneous Melanoma
Drug: Crizotinib
Drug: IDE196

Phase 1, Phase 2

Ideaya Biosciences

Saint Joseph, Missouri, United States and 13 other locations

The purpose of this study is to further evaluate the efficacy and safety of niraparib in patients with locally advanced or metastatic solid tumors an...

Active, not recruiting
Melanoma
Solid Tumor
Drug: Niraparib

Phase 2

Tempus AI
Tempus AI

Saint Joseph, Missouri, United States and 79 other locations

The primary objectives of this study are to:* Evaluate the safety and tolerability of AMG 355 as monotherapy and in combination with pembrolizumab in...

Enrolling
Advanced Solid Tumors
Drug: AMG 355
Drug: Pembrolizumab

Phase 1

Amgen
Amgen

Merriam, Kansas, United States and 5 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems